Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees Pharmaceutical Investing
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023 Pharmaceutical Investing
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million Pharmaceutical Investing
Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference Pharmaceutical Investing
BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT Combination in Advanced Metastatic Breast Cancer Technology Investing News
JUVÉDERM® VOLUX XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE Pharmaceutical Investing
Abbott Receives FDA Approval for Navitor, a Next-Generation TAVI System Designed to Treat Aortic Stenosis Pharmaceutical Investing
Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx for the Treatment of Recurrent Pericarditis Pharmaceutical Investing
